Skip to main content

Table 1 Clinicopathologic features of the patients included in this study according to their biomarker status

From: Combined analysis of PTEN, HER2, and hormone receptors status: remodeling breast cancer risk profiling

 

HR+/HER2-

HER2+

HR−/HER2-

Total

All patients, n (%)

488 (80)

50 (8)

70 (12)

608 (100)

Age, n (%)

 ≥ 55 years

350 (83)

32 (8)

38 (9)

420 (69)

 < 55 years

138 (73)

18 (10)

32 (17)

188 (31)

Menopause, n (%)

 Yes

383 (82)

41 (9)

44 (9)

468 (77)

 No

103 (76)

8 (6)

25 (18)

136 (22)

 n/a

2 (50)

1 (25)

1 (25)

4 (1)

Histology, n (%)

 Ductal

365 (79)

45 (10)

52 (11)

462 (76)

 Lobular

71 (92)

3 (4)

3 (4)

77 (13)

 Other

52 (75)

2 (3)

15 (22)

69 (11)

Grade, n (%)

 1

68 (94)

1 (1)

3 (4)

72 (12)

 2

240 (93)

11 (4)

7 (3)

258 (42)

 3

180 (65)

38 (14)

60 (22)

278 (46)

ER, n (%)

 Positive

488 (92)

40 (8)

0 (0)

528 (87)

 Negative

0 (0)

10 (13)

70 (88)

80 (13)

PgR, n (%)

 Positive

418 (93)

30 (7)

0 (0)

448 (73)

 Negative

70 (44)

20 (12)

70 (44)

160 (27)

HER2, n (%)

 Positive

0 (0)

50 (100)

0 (0)

50 (8)

 Negative

488 (87)

0 (0)

70 (13)

558 (92)

Ki67, n (%)

 High

267 (72)

63 (11)

61 (17)

369 (61)

 Low

221 (92)

9 (4)

9 (4)

239 (39)

Stage, n (%)

 I

228 (85)

19 (7)

21 (8)

268 (44)

 II

172 (77)

15 (7)

35 (16)

222 (37)

 III-IV

87 (74)

16 (14)

14 (12)

117 (19)

 n/a

1 (100)

0 (0)

0 (0)

1

Molecular subtype, n (%)

 Luminal Aa

204 (100)

0 (0)

0 (0)

204 (38)

 Luminal Bb

284 (88)

40 (12)

0 (0)

324 (49)

 HER2-type1c

0 (0)

10 (100)

0 (0)

10 (2)

 TNBCd

0 (0)

0 (0)

70 (100)

70 (11)

  1. HR Hormone receptors, ER Estrogen receptor, PgR Progesterone receptor, TNBC Triple-negative breast cancer, n/a not available; aER+/PR+/Ki67 low; bER+/Ki67 high or ER+/PR-; cER−/PR−/HER2+; dER−/PR−/HER2-